drugset / Trial / NCT06442462
Study of SPG302 in Adults With Schizophrenia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-03
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SPG302 | Small molecule | 300 mg | — |